Decristoforo Clemens
Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria.
Curr Radiopharm. 2012 Jul;5(3):212-20. doi: 10.2174/1874471011205030212.
(68)Ge/(68)Ga generators have received tremendous attention in the last years based on the success of (68)Ga-labelled Somatostatin analogues for Positron-Emission Tomography (PET), which are today used routinely worldwide. Various commercially available generator types are based on different column matrices including TiO(2), SnO(2) or organic (68)Gechelate coated silica, providing (68)Ga as Ga(3+) in HCl for radiolabeling procedures. These systems can serve as a stable source of (68)Ga for PET applications over periods of more than one year with high yields. A number of methods for post processing of the eluate including fractionation, anion or cation exchange purification have been developed. These methods are particularly important for high specific activity labeling of biomolecules such as peptides ensuring small volumes, low metallic contamination and low (68)Ge breakthrough. These systems have been implemented into fully automated modules allowing generator elution, post processing radiolabeling and formulation, complying with high regulatory demands. Quality aspects regarding the clinical use of (68)Ga for patient applications including limit of (68)Ge content, metal contamination, microbiological safety and radiochemical purity have been addressed. Overall, the establishment of (68)Ge/(68)Ga generator technology together with the development of novel (68)Ga-radiopharmaceuticals make (68)Ga a most promising radionuclide for PET in the years to come.
基于用于正电子发射断层扫描(PET)的68Ga标记生长抑素类似物的成功,68Ge/68Ga发生器在过去几年中受到了极大关注,目前这类类似物在全球范围内被常规使用。各种市售的发生器类型基于不同的柱基质,包括TiO(2)、SnO(2)或有机68Ge螯合物包被的二氧化硅,在HCl中以Ga(3+)形式提供68Ga用于放射性标记程序。这些系统可作为68Ga的稳定来源,用于PET应用,产量高,可使用一年以上。已经开发了许多用于洗脱液后处理的方法,包括分馏、阴离子或阳离子交换纯化。这些方法对于生物分子(如肽)的高比活度标记尤为重要,可确保小体积、低金属污染和低68Ge突破。这些系统已被应用于全自动模块中,可实现发生器洗脱、后处理放射性标记和制剂配制,符合严格的监管要求。已经讨论了关于68Ga在患者应用中的临床使用的质量方面,包括68Ge含量限制、金属污染、微生物安全性和放射化学纯度。总体而言,68Ge/68Ga发生器技术的建立以及新型68Ga放射性药物的开发使68Ga成为未来几年PET中最有前途的放射性核素。